Side effect |
Estradiol undecylate 100 mg/month i.m. (n = 96) |
Cyproterone acetate 100 mg/day oral (n = 95) | ||
---|---|---|---|---|
n | % | n | % | |
Gynecomastia* | 74 | 77.1% | 12 | 12.6% |
Breast tenderness* | 84 | 87.5% | 6 | 6.3% |
Sexual impotence | "Occurred in essentially all patients of both groups"
| |||
Leg edema* | 17 | 17.7% | 4 | 4.2% |
Thrombosis | 4 | 4.2% | 5 | 5.3% |
Cardiovascular mortality | 2 | 2.1% | 2 | 2.1% |
Other mortality | 1a | 1.0% | 0 | 0% |
Notes: For 6 months in 191 men age 51 to 88 years with prostate cancer. Footnotes: * = Differences in incidences between groups were statistically significant. a = Due to unknown causes. Sources: [1] [2] [3] |
Side effect |
Estradiol undecylate 100 mg/month i.m. (n = 96) |
Cyproterone acetate 100 mg/day oral (n = 95) | ||
---|---|---|---|---|
n | % | n | % | |
Gynecomastia* | 74 | 77.1% | 12 | 12.6% |
Breast tenderness* | 84 | 87.5% | 6 | 6.3% |
Sexual impotence | "Occurred in essentially all patients of both groups"
| |||
Leg edema* | 17 | 17.7% | 4 | 4.2% |
Thrombosis | 4 | 4.2% | 5 | 5.3% |
Cardiovascular mortality | 2 | 2.1% | 2 | 2.1% |
Other mortality | 1a | 1.0% | 0 | 0% |
Notes: For 6 months in 191 men age 51 to 88 years with prostate cancer. Footnotes: * = Differences in incidences between groups were statistically significant. a = Due to unknown causes. Sources: [1] [2] [3] |